Recordati

October 10, 2018

Mid-cap investors see Eastern promise in the third quarter

Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap players.

Mid-cap investors see Eastern promise in the third quarter

Shikeda masks slow second quarter for buyouts

Recordati deal points the way to a new private equity sweet spot

Back to the future for small caps, but not all benefit

Strong small cap performance drives second-quarter gains

Astrazeneca's dealing cannot mask its problems

Event – Erytech looks to pancreatic cancer data for uplift

Upcoming events: High-risk readouts for Erytech and Heron

Erytech wraps up successful pivotal study with leukaemia therapy

Upcoming events: Pivotal data for Seattle Genetics and Erytech

Investors waking up to Nymox

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Car-T sales have disappointed, but has the sellside’s outlook shifted enough?

$1bn Corindus deal gets Healthineers off the acquisition blocks

Clovis investors feel more Lynparza pressure

A recap on the past few months of data digging and analysis

Oncology's haves and have-nots